AIM
AIM ImmunoTech Inc.
$0.29
+0.00 (+0.00%)
At close · Jul 9
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.”View the 10-Q filed May 15, 2026
Market Cap
$4.12M
Shares
14,563,515
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.29
Open$0.30
Day$0.28–0.30
52W$0.21–19.74
Avg vol 30d39.6M
Short int2.2M · 15.1% float · 1.0d
Short vol48%
Last earningsJun 4, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 15
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−74%
below
Price vs 50-day avg
−29%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−28%
trailing
6-month return
−77%
trailing
YTD return
−74%
this year
Relative strength
−86%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+38% holders QoQ · +8 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.12% of float · ▼ -31.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
18 holders — near 1-yr high, broad support
Squeeze score
44
elevated · 0–100
Fundamentals
Revenue growth
−48%
Y/Y
EPS growth
+72%
Y/Y
Free cash flow
$-11.0M
Balance sheet
$1.5M
net debt
Quant / Vol
risk profile
Volatility
213%
annualized · 1-yr
Max drawdown
−97%
past year
ATR
22.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−74%
Bearish
Price vs 50-day avg
−29%
Bearish
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+38% holders QoQ · +8 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.12% of float · ▼ -31.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
18 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $0
Now $0 · 0%
52-wk high $20
vs 200-day avg -74%
vs 50-day avg -29%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AIM
this stock
AIM ImmunoTech Inc.
|
$4.12M | -73.5% | -48.2% | — | 15.1% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +9.5% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.63B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +8.2% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AIM | -3.3% | -27.5% | -77.2% | +3.6% | -73.5% |
| SPY | +0.8% | +2.0% | +8.9% | +0.7% | +10.2% |
| vs SPY | -4.1% | -29.5% | -86.1% | +2.9% | -83.8% |